DNLI Denali Therapeutics Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1714899 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY37.0%
TTM EPS YoY41.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-33.9%
ROA-27.2%
ROIC (approx.)-50.8%
Asset turnover—
Leverage & solvency
Liabilities / assets26.2%
Debt / equity0.00x
Current ratio6.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.41x
Accruals ratio11.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $0 |
| R&D expense | $418.78M | $396.44M |
| SG&A expense | $136.56M | $105.44M |
| Operating income | -$555.34M | -$487.34M |
| Income tax | $102,000 | $68,000 |
| Net income | -$512.54M | -$422.77M |
| EBITDA | -$544.16M | -$479.55M |
| EPS (basic) | -2.97 | -2.57 |
| EPS (diluted) | -2.97 | -2.57 |
| Weighted avg. shares (diluted) | 172.65M | 164.47M |
| Balance sheet | ||
| Cash & equivalents | $205.33M | $176.53M |
| Short-term investments | $662.55M | $657.37M |
| Receivables | $0 | — |
| Inventory | $0 | — |
| Current assets | $900.66M | $864.44M |
| PP&E, net | $52.40M | $55.24M |
| Intangibles | $0 | — |
| Total assets | $1.14B | $1.37B |
| Current liabilities | $98.35M | $102.21M |
| Total liabilities | $131.09M | $144.50M |
| Shareholders' equity | $1.01B | $1.23B |
| Shares outstanding | 156.18M | 144.22M |
| Cash flow statement | ||
| Operating cash flow | -$412.60M | -$347.69M |
| Capital expenditure | $9.50M | $15.91M |
| Free cash flow | -$422.10M | -$363.61M |
| Investing cash flow | $255.28M | -$88.76M |
| Financing cash flow | $189.22M | $484.30M |
| Depreciation & amortization | $11.18M | $7.79M |
| Stock-based compensation | $99.63M | $102.88M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.